Schuller D E, King G W, Smith R E, Wilson H E, James A D, Batley F
Laryngoscope. 1980 Aug;90(8 Pt 1):1263-72.
Combined therapy programs have improved recurrent and nodal metastatic rates but have not controlled distant metastases. A pilot study undertaken at Ohio State University evaluated the feasibility of adding chemotherapy to a combined modality regimen. The first phase determined that the toxicity of a four-drug combination chemotherapy yielded a favorable risk/benefit ratio and justified its inclusion in a protocol for untreated cancers. The second phase evaluated chemotherapy followed by surgery and postoperative irradiaation for untreated Stage III and IV epidermoid carcinoma of the oral cavity, oropharynx or hypopharynx. The overall chemotherapy response rate is 88% (22/25) with 6 complete and 16 partial responses. Evaluation of pathology specimens revealed 7 of 14 primary sites and 4 of 15 neck specimens had no histologic evidence of carcinoma. In the 10 patients who received all 3 modalities, 9 are free of disease (6 to 17 mo. follow-up).
联合治疗方案已提高了复发率和淋巴结转移率，但未能控制远处转移。俄亥俄州立大学开展的一项初步研究评估了在联合治疗方案中加入化疗的可行性。第一阶段确定，四种药物联合化疗的毒性产生了良好的风险/效益比，证明将其纳入未治疗癌症的方案是合理的。第二阶段评估了化疗后进行手术及术后放疗，用于治疗未经治疗的口腔、口咽或下咽III期和IV期表皮样癌。总体化疗缓解率为88%（22/25），其中6例完全缓解，16例部分缓解。病理标本评估显示，14个原发部位中的7个和15个颈部标本中的4个没有癌组织学证据。在接受了所有三种治疗方式的10例患者中，9例无疾病（随访6至17个月）。
